Among the companies whose shares are expected to see active trade in Friday’s session are Oracle, Smith & Wesson, and Family Dollar. Powered by WPeMatico
The Nasdaq Stock Market® Welcomes 14 New ETPs in the Second Quarter of 2017Powered by WPeMatico
|
Seattle biotech Alpine Immune Sciences goes public through merger
The Seattle Times Seattle's newest publicly traded biotechnology company, Alpine Immune Sciences, made its market debut Monday with a 5 cent dip to close at $9.55. The company went public by merging with another biotech, Nivalis Therapeutics of Boulder, Colo., which ... and more » |
MarketWatch |
Opinion: Three biotech companies to watch ahead of earnings
MarketWatch Outside of biotech, CAI International Inc. CAI, -2.38% is seeing excellent follow-through from last Friday, when price popped all the way up to a high of $26.12. On Monday the stock gained $1, or 3.8%, to close at a three-year high of $26.93 on 427,600 ... and more » |
Zacks.com |
Can Biotech ETFs Continue to Surge Higher?
Zacks.com Although biosimilars are yet to pick pace, they remain a major threat for biotech stocks specially companies that are set to lose patent protection for major blockbuster drugs in the next few years. While a relatively new area, the market for ... |
Seeking Alpha |
Biotech Bonanza: The Next Leg Up
Seeking Alpha In our timely article, Biotech's Best Chance, and its follow-up Biotech's Best Chance Gets Even Better, we had outlined a number of imminent reasons for a Biotech rally to ensue. The arguments remain compelling, particularly the emerging FDA focus, and ... and more » |
Investor's Business Daily |
This Biotech Nearly Tripled Street Expectations For One Key Drug
Investor's Business Daily ... revenue grew 6% though profits sank 3.3%. On the stock market today, Biogen fell 0.6% to close at 282.96, after gaining as much as 4.3% before the open. Shares hit their highest point since April 25 while biotech stocks were generally flat early ... and more » |
TheStreet.com |
Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite
TheStreet.com Shares of vaccine company Novavax Inc. (NVAX) were down 24% to $1.15 early Tuesday afternoon. The Gaithersburg, Md.-based firm after the market close on Monday reported positive topline data from its Phase 2 safety and immunogenicity trial of the RSV ... Novavax, Inc. - NVAX - Stock Price Today - ZacksZacks Investment Research all 102 news articles » |
FierceBiotech |
Regenerative biotech Rodeo gains WuXi, Lilly, AbbVie backing ...
FierceBiotech Rodeo Therapeutics Corporation has got off a $5.9 million series A financing round with a list of VC and biopharma all-stars as backers. and more » |
Zacks.com |
Boosts in R&D Spending Drive Biotech Innovation, BDO USA Analysis Finds
CPAPracticeAdvisor.com Fueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in research and development (R&D), according to the sixth annual study from BDO USA, LLP. The 2017 ... Biotech ETF Industry Outlook for Second Half 2017Zacks.com all 2 news articles » |